Evaluation of anti-cancer therapy using in silico analysis of treatments for HER2+ breast cancer

IEEE MeMeA 2014 - IEEE International Symposium on Medical Measurements and Applications, Proceedings

Volumn , Issue , 2014, Pages

  Ganic, Emir ^a   Gundry, Stephen ^b   Zou, Jianmin ^b   Uyar, M Umit ^b  

^a POLYTECHNIC UNIVERSITY   (United States)

^b UNIVERSITY OF NEW YORK   (United States)

Author keywords

Cancer; Chemotherapy; Decision support system; In silico; Nccn; Pharmacodynamics; Pharmacokinetics; Targeted medicine; Tumor growth models

Indexed keywords

ARTIFICIAL INTELLIGENCE; BIOLOGICAL MATERIALS; CHEMOTHERAPY; DECISION SUPPORT SYSTEMS; MONOCLONAL ANTIBODIES; PHARMACODYNAMICS; PHARMACOKINETICS;

ANTI-CANCER THERAPIES; BREAST CANCER XENOGRAFTS; CANCER; CLINICAL DECISION SUPPORT; HUMAN BREAST CANCER; IN-SILICO; NCCN; TUMOR GROWTH MODELS;

DISEASES;

EID: 84906895338     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/MeMeA.2014.6860059     Document Type: Conference Paper

References (23)

1. "Clinical practice guidelines in oncology: Breast cancer," National Comprehensive Cancer Network, http://www.nccn.org.
2. J. Harrold and R. Parker, "Clinically relevant cancer chemotherapy dose scheduling via mixed-integer optimization," Computers & Chemical Engineering, vol. 33, no. 12, pp. 2042-2054, 2009.
3. M. Rocchetti, M. Simeoni, E. Pesenti et al., "Predicting the active doses in humans from animal studies: A novel approach in oncology," European Journal of Cancer, vol. 43, no. 12, pp. 1862-1868, 2007.
4. A. Chakraborty and W. J. Jusko, "Pharmacodynamic interaction of re-combinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation," Journal of pharmaceutical sciences, vol. 91, no. 5, pp. 1334-1342, 2002.
5. E. D. Lobo and J. P. Balthasar, "Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro," AAPs PharmSci, vol. 4, no. 4, pp. 212-222, 2002.
6. J. Kusyk, C. Sahin, M. Uyar, E. Urrea, and S. Gundry, "Self organization of nodes in mobile ad hoc networks using evolutionary games and genetic algorithms," Journal of Advanced Research, vol. 2, no. 3, pp. 253-264, 2011.
7. J. Zou, S. Gundry, J. Kusyk, M. U. Uyar, and C. S. Sahin, "3D genetic algorithms for underwater sensor networks," International Journal of Ad Hoc and Ubiquitous Computing, vol. 13, no. 1, pp. 10-22, 2013.
8. C. Sahin, M. U. Uyar, S. Gundry, and E. Urrea, "Self organization for area coverage maximization and energy conservation in mobile ad hoc networks," in Transactions on Computational Science XV. Springer, 2012, pp. 49-73.
9. L. Norton, "Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy," The Oncologist, vol. 10, no. 6, pp. 370-381, 2005.
10. Y. Jin, J. Li, Y. Huang et al., "Pharmacokinetics and tissue distribu-tion of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice1," Acta Pharmacologica Sinica, vol. 26, no. 2, pp. 250-256, 2005.
11. Y. Cao and W. J. Jusko, "Applications of minimal physiologically-based pharmacokinetic models," Journal of pharmacokinetics and pharmacodynamics , vol. 39, no. 6, pp. 711-723, 2012.
12. M. Germani, F. D. Bene, M. Rocchetti et al., "A4s: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (pk/pd) sim-ulation," Computer Methods and Programs in Biomedicine, vol. 110, no. 2, pp. 203-214, 2013.
13. J. Yang, D. E. Mager, and R. M. Straubinger, "Comparison of two pharmacodynamic transduction models for the analysis of tumor thera-peutic responses in model systems," The AAPS journal, vol. 12, no. 1, pp. 1-10, 2010.
14. K. Goteti, C. E. Garner, L. Utley et al., "Preclinical pharmacoki-netic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents," Cancer chemotherapy and pharmacology , vol. 66, no. 2, pp. 245-254, 2010.
15. A. Heatherington, P. Vicini, and H. Golde, "A pharmacokinet-ic/ pharmacodynamic comparison of saam ii and pc/winnonlin modeling software." J Pharm Sci, vol. 87, no. 10, pp. 1255-63, 1998.
16. T. Callegari, A. Caumo, and C. Cobelli, "Generalization of map estimation in SAAM II: validation against ADAPT II in a glucose model case study," Annals of Biomedical Engineering, vol. 30, no. 7, pp. 961-968, Jul-Aug 2002.
17. N. Terranova and P. Magni, "Tgi-simulator: A visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug," Computer Methods and Programs in Biomedicine, vol. 105, no. 2, pp. 162-174, 2012.
18. Q. Liua, Q. Sua, G. Luoa, Y. Wanga, and Q. Zanga, "Pharmacokinetics and tissue distribution of carboplatin liposomes after intravenous ad-ministration to mice," Asian J Pharm Sci, vol. 1, no. 3-4, pp. 159-167, 2006.
19. Z. Hassana and M. Hassan, "Cyclophosphamide pharmacokinetics in mice: a comparison between retro orbital sampling versus serial tail vein bleeding," Open Pharmacology Journal, vol. 1, pp. 30-35, 2007.
20. M. D. Pegram, G. E. Konecny, C. O'Callaghan et al., "Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer," Journal of the National Cancer Institute, vol. 96, no. 10, pp. 739-749, 2004.
21. S. Reagan-Shaw, M. Nihal, and N. Ahmad, "Dose translation from animal to human studies revisited," The FASEB Journal, vol. 22, no. 3, pp. 659-661, 2008.
22. M. Pegram, S. Hsu, G. Lewis, R. Pietras, M. Beryt et al., "Inhibitory effects of combinations of her-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers," Oncogene, vol. 18, no. 10, pp. 2241-2251, 1999.
23. Y. Wang, W. Liu, Z. Ji, Z. Zhang, J. Wang, X. Yan, and X. Zhang, "The effects of various chemotherapy regimens on the expression of pcna and human breast cancer xenograft (mcf-7) transplanted in nude mice," The Chinese-German Journal of Clinical Oncology, vol. 6, no. 5, pp. 474-478, 2007.